Shionogi Grows Rare Disease Portfolio with $2B IntraBio Acquisition
Shionogi signaled its intent to focus on rare disease drugs in April when it acquired Radicava (edaravone), an amyotrophic lateral sclerosis (ALS) treatment, from Tanabe Pharma for $2.5 billion and potential royalties. The post Shionogi Grows Rare Disease Portfolio with $2B IntraBio Acquisition appeared first on GEN - Genetic Engineering and Biotechnology News .
Japanese pharmaceutical company Shionogi has agreed to acquire IntraBio for $2 billion, with the aim of expanding its portfolio of rare disease treatments, particularly in the U.S. and European Union markets. The acquisition includes Aqneursa, a drug approved by the FDA in September 2024 and the European Medicines Agency in January to treat neurological manifestations of Niemann-Pick disease type C (NPC) and ataxia in ataxia-telangiectasia patients.
Shionogi's president and CEO, Isao Teshirogi, emphasized the company's commitment to rare disease research and the value of Aqneursa in addressing unmet patient needs. The acquisition comes after Shionogi's recent approval of a supplemental New Drug Application for Aqneursa, expanding its label to include ataxia-telangiectasia. The deal, which is subject to customary closing conditions, follows Shionogi's previous acquisition of Radicava, a treatment for amyotrophic lateral sclerosis (ALS), in April.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
